Meeting
2013 ASCO Annual Meeting
The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM).
Authors
LF Zhou
Department of Neurosurgery, Huashan Hospital SMC FDU, Shang Hai, China
LF Zhou , Yu Yao , Shuyuan Yang , Xuejun Yang , Xiang Wang , Xiang Zhang , Liwei Zhang , Yicheng Lu , Zhong-ping Chen , Jianmin Zhang , Songtao Qi , Renzhi Wang , Chao You , Ying Mao , Jisheng Wang , Juxiang Chen , Qun-ying Yang , Hong Shen , Zhiyong Li , Ma WB
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00686725
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2022)
DOI
10.1200/jco.2013.31.15_suppl.2022
Abstract #
2022
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2022 ASCO Annual Meeting
Phase IB trial of pegylated arginine deiminase (ADI-PEG 20) plus radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: John S. Bomalaski
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2012 ASCO Annual Meeting
A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.
First Author: Elma S. Hawkins